Pharma BD Deal Intelligence
Sumitomo simply finished what it started: Sumitovant paid $27.00/share cash to mop up the Myovant minority it didn't already own, valuing that stake at $1.7B and the whole company at $2.9B, revised up from a rejected prior offer.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Sumitomo Pharma's $1.7 billion deal to absorb Myovant Sciences ends a years-long ownership uncertainty around the relugolix franchise, which Sumitomo helped…
Myovant Sciences and Sumitovant Biopharma today announced a definitive merger agreement under which Sumitovant will acquire all outstanding common shares of…
Myovant reported third quarter fiscal 2022 net product revenue of $58.6 million, up 116% year over year, driven by Orgovyx growth in advanced prostate cancer…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Sumitovant Biopharma agreed to acquire all outstanding Myovant shares it did not already own (Sumitomo held ~52%) at $27.00/share cash, valuing the minority at $1.7B and total company at $2.9B. The deal was a definitive agreement on Oct 24, 2022 (revised up from prior offer).
26M US cases/yr · $4.5B Global GnRH antagonist women's health market (2022) · ~600,000 U.S. annual hysterectomies
Uterine fibroids affect an estimated 26 million U.S. women of reproductive age, with roughly 5 million experiencing symptomatic disease characterized by heavy menstrual bleeding, pelvic pain, anemia, and reduced fertility. Endometriosis, the ectopic implantation of endometrial-like tissue outside the uterus, affects approximately 1 in 10 reproductive-age women (~6.5 million U.S.) and is a leading cause of chronic pelvic pain, dyspareunia, and infertility. Both conditions are GnRH-axis driven, creating a unifying pharmacology around suppression of pituitary gonadotropin signaling. The commercial center of gravity sits with oral GnRH antagonist combination products that pair receptor blockade with low-dose estradiol and norethindrone add-back to mitigate hypoestrogenic side effects, particularly bone mineral density loss and vasomotor symptoms. Hysterectomy and surgical excision remain mainstays for refractory disease but carry substantial morbidity and recovery cost burden. Payer coverage of branded oral antagonists has expanded materially since 2020, though step-edit through generic GnRH agonists (leuprolide depot) and NSAIDs persists in many commercial plans. The franchise opportunity behind the Myovant acquisition centers on Myfembree (relugolix combination), the only once-daily co-formulated antagonist tablet approved across both fibroids and endometriosis indications in the United States, providing a single-product franchise spanning two large women's health markets.
The oral GnRH antagonist class is a three-horse race that defines the modern women's health hormonal franchise. Myfembree (relugolix 40mg + estradiol 1mg + norethindrone 0.5mg, Myovant/Pfizer ex-U.S.) is the only once-daily co-formulated single tablet approved across both heavy menstrual bleeding from fibroids (FDA May 2021) and moderate-to-severe endometriosis pain (FDA Aug 2022), giving it a unique single-tablet positioning. Oriahnn (elagolix + estradiol/norethindrone, AbbVie) was first-in-class for fibroids but uses an inconvenient twice-daily morning/evening split-dosing regimen and has lost share post-Myfembree launch. Orilissa (elagolix monotherapy, AbbVie) remains the leading branded oral for endometriosis pain but carries 6-month duration limits at the higher dose because of bone-density risk. Injectable depot GnRH agonists (Lupron Depot leuprolide acetate, AbbVie; Zoladex goserelin, AstraZeneca; Synarel nafarelin, Pfizer) remain the genericized backbone but cause initial flare and require add-back. Tranexamic acid (Lysteda) and the levonorgestrel intrauterine system (Mirena) cover non-hormonal and local options. Sumitomo's acquisition consolidates full U.S. economic ownership of the leading once-daily co-formulated antagonist franchise across both indications.
288K US cases/yr · $12.0B Global prostate cancer therapeutics market (2022) · ~34,700 U.S. annual prostate cancer deaths
Prostate cancer is the second most common cancer in U.S. men, with approximately 288,300 new cases and 34,700 deaths projected annually. Advanced disease (locally advanced or metastatic, hormone-sensitive or castration-resistant) accounts for the lion's share of pharmaceutical economics in the tumor type. Androgen deprivation therapy (ADT) remains the foundation of treatment, traditionally delivered via injectable LHRH/GnRH agonists or surgical castration. Oral GnRH receptor antagonism, pioneered by relugolix (Orgovyx), offers rapid testosterone suppression without the initial testosterone flare seen with agonists, no requirement for clinic injections, faster testosterone recovery upon discontinuation, and a Part D distribution path versus Part B buy-and-bill economics. The shift to oral ADT, plus novel hormonal agent (NHA) intensification with abiraterone/enzalutamide/apalutamide/darolutamide, and PARP inhibitors (Lynparza, Talzenna, Akeega) for HRR-mutant mCRPC, has reshaped the segment over the past five years. Orgovyx's commercial trajectory benefits materially from urologist office workflow simplification and Medicare Part D coverage relative to legacy injectables.
Advanced prostate cancer hormonal therapy splits across multiple MOA classes that compete on intensification, route of administration, and biomarker selection across multiple lines of therapy. Oral GnRH antagonist is owned exclusively by Orgovyx (relugolix, Myovant/Pfizer ex-U.S.), FDA-approved December 2020 for advanced prostate cancer. Injectable GnRH/LHRH agonists are dominated by Lupron Depot (leuprolide acetate, AbbVie), Eligard (leuprolide, Tolmar), Zoladex (goserelin, AstraZeneca), Trelstar (triptorelin, Verity), and various generic depots. Injectable GnRH antagonist Firmagon (degarelix, Ferring) preceded Orgovyx but requires monthly subcutaneous clinic injections with painful injection-site reactions. Novel hormonal agents intensifying ADT include Xtandi (enzalutamide, Pfizer/Astellas), Erleada (apalutamide, Janssen), Nubeqa (darolutamide, Bayer/Orion), and Zytiga/Yonsa (abiraterone acetate, Janssen/Sun, plus multiple generics). PARP inhibitors for HRR-mutant mCRPC include Lynparza (olaparib, AstraZeneca/Merck), Talzenna (talazoparib, Pfizer with enzalutamide combination), and Akeega (niraparib + abiraterone, Janssen). Pluvicto (Lu-177 PSMA-617, Novartis) is the leading radioligand entrant in PSMA-positive mCRPC, and Xofigo (radium-223, Bayer) covers bone-metastatic disease. Sumitomo's deal consolidates full U.S. ownership of the only oral GnRH antagonist in advanced prostate cancer.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sumitomo Pharma / Sumitovant Biopharma / Myovant Sciences Ltd. (this deal) | 2022 | $1.7B | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
| Servier Pharmaceuticals LLC / Agios Pharmaceuticals Inc. | 2020 | $2.0B | 91 |
← Browse all deals · How we score deals
More: 2022 deals · Oncology deals